SPOTLIGHT: S&P likes GTx's Acapodene


Standard & Poor's Equity Research says that GTx is in an enviable position. Late-stage data is due this quarter for Acapodene, an experimental therapy for prostate cancer. "We believe both target markets represent population opportunities of more than 1 million patients." Report